SCHEMBL23540790

SCHEMBL23540790

COC(=O)CN(c1c(OCc2ccccc2)cc2cc(Br)ccc2c1F)S(N)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 1/20 0.46
KEAP1 Q14145 5/20 0.41
NFE2L2 Q16236 5/20 0.41
PTPN1 P18031 3/20 0.39
PTPN2 P17706 2/20 0.39
PTPN6 P29350 2/20 0.39
LMNA P02545 2/20 0.39
USP2 O75604 1/20 0.39
LRRK2 Q5S007 4/20 0.38
PTPRF P10586 1/20 0.37
PTPN11 Q06124 1/20 0.37
HTT P42858 1/20 0.36
MMP1 P03956 1/20 0.36
MMP9 P14780 1/20 0.36
MMP13 P45452 1/20 0.36
CYP19A1 P11511 1/20 0.35
PTGER1 P34995 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30026629 1.00 ALDH1A1 (0.46) ALDH1A1MAPK1KEAP1NFE2L2PTPN1
SCHEMBL31277111 0.93 ALDH1A1 (0.46) ALDH1A1MAPK1KEAP1NFE2L2PTPN1
SCHEMBL30026693 0.93 ALDH1A1 (0.46) ALDH1A1MAPK1KEAP1NFE2L2PTPN1
SCHEMBL23540306 0.93 ALDH1A1 (0.46) ALDH1A1MAPK1KEAP1NFE2L2PTPN1
SCHEMBL22412649 0.91 KEAP1 (0.50) KEAP1NFE2L2LMNALRRK2HTT
SCHEMBL30027118 0.85 ALDH1A1 (0.43) ALDH1A1MAPK1KEAP1NFE2L2PTPN1
SCHEMBL23540005 0.85 ALDH1A1 (0.43) ALDH1A1MAPK1KEAP1NFE2L2PTPN1
SCHEMBL2892950 0.84 ALDH1A1 (0.48) ALDH1A1MAPK1KEAP1NFE2L2PTPN1
SCHEMBL22412423 0.83 KEAP1 (0.50) KEAP1NFE2L2LMNALRRK2HTT
SCHEMBL28576993 0.81 ALDH1A1 (0.44) ALDH1A1MAPK1KEAP1NFE2L2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 US disclosed
CN-116348455-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2023-06-27 CN disclosed
CN-116332873-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2023-06-27 CN disclosed
EP-4077319-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-10-26 EP disclosed
CN-114025844-B Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2022-07-26 CN disclosed
CN-114025844-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2022-02-08 CN disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 ALDH1A1 2836/4885MAPK1 823/4885KEAP1 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.